´â¼­Åµ
  ÏÀʸ°ìÍ÷¡¡Ê¬³äɽ¼¨¡¡1¡¿10
´Ê°×¸¡º÷
¡¡   
¡¡
¥ê¥¹¥È¹¹¿·¡§2008/03/01(Sat) 05:13 JST
¹¹¿·¤Ï½ªÎ»¤·¤Þ¤·¤¿ ºÇ¿·¤Ï ʬ³äɽ¼¨¡¡1¡¿10

£±ÊÇɽ¼¨¤Ï¡¡¤³¤Á¤é¡£¡¡¡¡¡¡ ¤³¤Á¤é¤â¡¡ÊIJͽñ¸Ë¡¦¥ê¥¹¥È°ìÍ÷


¼ýÏ¿ÏÀʸ¡¡Á´[3889]·ïÃæ¡¡¥¢¥ë¥Õ¥¡¥Ù¥Ã¥È½ç[400]·ï

1¡¿10¡¡ 2¡¿10¤Ø¡¡ 3¡¿10¤Ø¡¡ 4¡¿10¤Ø¡¡ 5¡¿10¤Ø¡¡ 6¡¿10¤Ø¡¡ 7¡¿10¤Ø¡¡ 8¡¿10¤Ø¡¡ 9¡¿10¤Ø¡¡ 10¡¿10¤Ø¡¡
¡¡
¡¡ÏÀʸ̾¶èʬ
"·õ»³Ë¡"MCT¤ò»Ü¹Ô¤·¤¿Ä¾·Â12cm¤ÎµðÂçÃÀ´ÉºÙ˦´â¤Î¼£Îŷи³ ¢¡´ÎÆâÃÀ´É´â ¾
1 °­À­¿À·Ðç±¼ð¤ËÂФ¹¤ë²¹Ç®¼£ÎŤˤè¤ëË̵þ¤Ø¤Î°åÎűç½õ22²ó¡¡Âç²ñ
10ǯ°Ê¾åÀ¸Â¸¤·¤¿´ÎºÙ˦´â¤Î5Îã¡¡¡¦¡¦¡¦¾ÉÎã¤ÎÆâÌõ¤È¼£ÎÅË¡¡¡£¶£¸ºÐ½÷À­..35ºÐÃËÀ­.. ¾ÉÎãÁí³ç¡¦¡¦ ¢¡´Î¡´â ¾
12ǯ´Ö¤Î·Ð²áÃæ¤ËExemestane¤¬Ãø¸ú¤·¤¿Æý´â¹üž°Ü¤Î1Îã ¢¡£··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾
13ºÐ½÷À­¤Ëȯ¾É¤·¤¿²£Ìæ¶ÚÆù¼ð¤Î1Îã¡¡¡¦¡¦¡¦Æý˼¸¶È¯²£Ìæ¶ÚÆù¼ð¾É¡¦¡¦ ¢¡8·îÂè2½µ(5Æü¡Ë ¾
18ǯ´Ö¤Ë7²ó¤ÎŦ½Ð½Ñ¤ò¹Ô¤Ã¤¿¸åÊ¢Ëì»éËÃÆù¼ð¤Î1Îã ¢¡£³·îÂ裴½µ¡§£²£¶Æü(ÅÚ¡Ë Â¾
1aaaaa¥Æ¥¹¥È¥Ç¡¼¥¿¤Ç¤¹¡¡¡¦¡¦¡¦¤¢ ¤¤ ¤¦ ¤¨ ¤ª ²Á³Ê¥¼¥í±ß¤Ç¡¡¡Ö¹ØÆþ¥Ü¥¿¥ó¡×¤¬½Ð¤Ê¤¤¤è¤¦¤Ë¡¦¡¦ ¢¡test ¾
2²ó¤Î¼«²ÈËö¾¿·ì´´ºÙ˦°Ü¿¢¸å¤â´²²ò¤òÆÀ¤é¤ì¤º,QOL½Å»ë¤ÎÊý¿Ë¤ÇĹ´ü´Ö´Ñ»¡¤·¤¨¤¿¿À·Ð²ê¼ð¤Î1Îã ¢¡£¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾
2²ó¤Î¼«²ÈËö¾¿·ì´´ºÙ˦°Ü¿¢Ê»ÍÑĶÂçÎ̲½³ØÎÅË¡¤Ë¤è¤ëµßºÑÎÅË¡¤ò¹Ô¤Ã¤¿Æñ¼£À­½Ä³ÖÀº¾åÈé¼ð¤Î1Îã33-06
2ǯÀ¸Â¸¤òÆÀ¤¿GemcitabineÅêÍ¿ÀÚ½üÉÔǽ¿Ê¹Ôç¹´â¤Î2Îã ¢¡ç¹Â¡´â ¾
3¼ïÎà¤Î´ÁÊýÌô¤Ë¤è¤ê·«¤êÊÖ¤µ¤ì¤¿ÌôʪÀ­´Î¾ã³²¤Î1Îã ¢¡´Î¡´â ¾
4·¿¥¹¥­¥ë¥¹°ß´â¤ÎÊ¢Ëìž°Ü¡¡¡¦¡¦¡¦Ê¢Ë잰ܤμ£ÎÅ¡¡ÈóÀÚ½ü¤ÈÀÚ½ü¤ÎÎ×¾²ÉÂÍý³ØÅªÆÃħ¤È¼£ÎÅÀ®ÀÓ¡¡Ê¢ËìÇżðÍÛÀ­¤ÈÇżð±¢À­¤òºÙ˦À­¡¦¡¦ ¢¡¥¹¥­¥ë¥¹ ¾
4·¿°ß´âº¬¼£½Ñ¸å¤Î¥ê¥ó¥ÑÀáºÆÈ¯¤ËTS-1¤¬Í­¸ú¤Ç¤¢¤Ã¤¿1Îã ¢¡°ß´â ¾
5'-Deoxy-5-Fluorouridine(5'-DFUR),Medroxyprogesterone Acetate(MPA),Cyclophosphamide(CPA)Ê»ÍÑÎÅË¡(DMpCÎÅË¡)¤¬ÁÕ¸ú¤·¤¿¿Ê¹ÔÆý´â¤Î2Îã ¢¡£··îÂ裴½µ¡§£²£´Æü¡ÊÆü¡Ë ¾
5'-DFUR + CPA + THPÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿PaclitaxelÄñ¹³À­Æý´âÇÙž°Ü¤Î1Îã ¢¡Æý´â ¾
5'-DFUR(5'-Deoxy-5-Fluorouridine)+MPA(Medroxyprogesterone Acetate)Ê»ÍÑÎÅË¡¤ÇĹ´ü´²²ò¤òÆÀ¤Æ¤¤¤ëºÆÈ¯Æý´â¤Î1¾ÉÎã ¢¡°ß´â ¾
5'-DFUR,CisplatinÎÅË¡,¼ê½ÑÎÅË¡¤Ë¤è¤ê½Ñ¸å10ǯ°Ê¾å̵ºÆÈ¯À¸Â¸¤òÆÀ¤Æ¤¤¤ë°ß´â¿ȯ´Îž°Ü¤Î1Îã ¢¡°ß´â ¾
5'-DFUR¡¦MPAÎÅË¡¤¬ÁÕ¸ú¤·¤¿ÀÔÄÇ¡¦ÀÔ¿ñž°Ü¤òȼ¤¦¿Ê¹ÔÆý´â ¢¡Æý´â ¾
5'-DFUR¡ÜMMCÊ»ÍÑÎÅË¡¤Ë¤è¤ê´°Á´´²²ò¤·¤¿ÂçIJ´â´Îž°Ü¤Î1Îã ¢¡ÂçIJ´â ¾
5'-DFUR¤¬Ãø¸ú¤·¤¿ÂçIJ´â´Îž°Ü¤Î1Îã ¢¡·ëIJ´â ¾
5'-DFUR¤Ë¤è¤ê¾Ã¼º¤·¤¿PyNPaseÍÛÀ­ÂçIJ´â¤Î¿ȯÀ­´Îž°Ü¤Î1Îã ¢¡Å¾°ÜÀ­´Î¡´â ¾
5'-DFURñºÞÅêÍ¿¤¬Ãø¸ú¤ò¼¨¤·¤¿¿Ê¹ÔÆý´â¤Î1Îã ¢¡Æý´â ¾
5'-DFURÄãÍÑÎÌÅêÍ¿¤È¥Û¥ë¥â¥óÎÅË¡¤ÎÊ»ÍѤ¬Í­¸ú¤Ç¤¢¤Ã¤¿ºÆÈ¯Æý´â¤Î1Îã ¢¡£··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾
5-Fluorouraci1/l-LeucovorinưÃíÎÅË¡¤Ë¤è¤êĹ´ü´Ö¿Ê¹Ô¤¬À©¸æ¤µ¤ì¤Æ¤¤¤ëľIJ´â¸¶È¯´Îž°Ü¤Î1¾ÉÎã ¢¡·ëIJ´â ¾
5-Fluorouracil/l-Leucovorin¤Ë¤è¤ëÁ´¿È²½³ØÎÅË¡¤¬Ãø¸ú¤·¤¿¿Ê¹ÔÂçIJ´â¤Î1Îã ¢¡ÂçIJ´â ¾
5-Fluorouracil/l-LeucovorinÎÅË¡¤¬ÁÕ¸ú¤·¤¿ÂçIJ´â´Îž°Ü¤Î2Îã ¢¡ÂçIJ´â ¾
5-Fluorouracil´ÎưÃíÎÅË¡Ãæ¤Ë¶¹¿´¾Éȯºî¤òÍ褷¤¿Å¾°ÜÀ­´Î´â¤Î1Îã ¢¡·ëIJ´â ¾
5-FU+Interferon-¦ÁÊ»ÍÑÎÅË¡¤Ë¤ª¤±¤ë5-FUÂå¼Õ´ØÏ¢¹ÚÁdzèÀ­¤Î¸¡Æ¤¡¾¥Ì¡¼¥É¥Þ¥¦¥¹²Ä°Ü¿¢À­¥Ò¥È´ÎºÙ˦´â³ô¤Ë¤ª¤±¤ë¸¡Æ¤ ¢¡´Î¡´â ¾
5-FU,Adriamycin,CDDP(FAP)¤Ë¤è¤ë3ºÞÊ»ÍÑ´ÎÆ°Ãí²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿¶É½ê¿Ê¹ÔÃÀ´ÉºÙ˦´â¤Î2Îã ¢¡ÃÀÆ»´â ¾
5-FU,CDDP,Adriamycin¤Î3ºÞÊ»ÍÑÆ°Ãí²½³ØÎÅË¡¤Ë¤è¤êCR¤¬ÆÀ¤é¤ì¤¿¿Ê¹Ô´ÎºÙ˦´â(Vp4,Vv3,IM3)¤Î1Îã ¢¡´Î¡´â ¾
5-FU/CPT-11ÅêÍ¿¤Ë¤è¤êCR¤¬ÆÀ¤é¤ì¤¿ÂçIJ´â½Ñ¸å¤Î´Îž°Ü¤ª¤è¤ÓÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀឰܤÎ1Îã ¢¡ÂçIJ´â ¾
5-FU/LV´Îư̮ÃíÆþ²½³ØÎÅË¡¤Ë¤è¤ëž°ÜÀ­´Î´â¼£ÎžÉÎã¤Î¸¡Æ¤ ¢¡·ëIJ´â ¾
5-FU/MMC/CDDP»°ºÞÊ»ÍÑÎÅË¡¸å¤ËTS-1ÎÅË¡¤ò¹Ô¤¤Í­¸ú¤Ç¤¢¤Ã¤¿ºÆÈ¯°ß´â¤Î3Îã ¢¡°ß´â ¾
5-FU¡¤CDDP¡¤Adriamycin(FAP)¤Ë¤è¤ë´ÎưÃí²½³ØÎÅË¡¤¬Ãø¸ú¤·¤¿¿Ê¹Ô´ÎºÙ˦´â¤Î2Îã ¢¡²½³ØÎÅË¡ ¾
5-FU¡¦¥í¥¤¥³¥Ü¥ê¥óÎÅË¡¤¬ÁÕ¸ú¤·¤¿½Ä³Ö¥ê¥ó¥ÑÀᡦ´Îž°Ü¤òÍ­¤¹¤ëľIJ´â¤Î1Îã ¢¡·ëIJ´â ¾
5-FU¤ò´Þ¤àÊ»ÍѲ½³ØÎÅË¡¤Ë̵¸ú¤È¤Ê¤Ã¤¿ºÆÈ¯·ëIJ¡¦Ä¾Ä²´â¾ÉÎã¤ËÂФ¹¤ëSecond-Line Chemotherapy¤È¤·¤Æ¤ÎBi-Weekly CPT-11+CDDPÊ»ÍÑÎÅË¡¤Î¸¡Æ¤ ¢¡·ëIJ´â ¾
5-FU´ÎưÃíÎÅË¡¤Ë¤ÆÈÆ·ìµå¸º¾¯,ARDS¤òÍ褷¤¿1Îã ¢¡Å¾°ÜÀ­´Î¡´â ¾
5-FU·Ï¹³´âºÞÄñ¹³À­¤Î¿Ê¹Ô¡¦ºÆÈ¯°ß´â¤ËÂФ¹¤ëWeekly PaclitaxelÎÅË¡¤ÎFeasibility Study ¢¡°ß´â ¾
5-FUưÃí¤ÈIFNÅêÍ¿¤Ë¤Æ³°Íè²ÃÎÅÃæ¤Î¤ÓÌ¡·¿´Î´â¤Î1Îã ¢¡´Î¡´â ¾
50ºÐ°Ê¾å¤Î·ì±Õ¼À´µ¤ËÂФ¹¤ëƱ¼ï¤·ì´´ºÙ˦°Ü¿¢ ¢¡£²·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾
5cmÂç¤Î¸åÊ¢ËìÊ¿³ê¶ÚÆù¼ð¤Î1Îã¡¡¡¦¡¦¡¦¾ÉÎã 57ºÐ,½÷À­ ¹Í»¡¡¡¡¦¡¦ ¢¡£³·îÂ裴½µ¡§£²£¶Æü(ÅÚ¡Ë Â¾
5¡­-DFUR,CimetidineÊ»ÍÑÎÅË¡¤Ë¤è¤êĹ´üÀ¸Â¸¤¬ÆÀ¤é¤ì¤¿ÂçIJ´âƱ»þÀ­Â¿È¯ÇÙž°Ü¤Î1Îã ¢¡ÂçIJ´â ¾
60Gy̤Ëþ¤ÎÊü¼ÍÀþ¼£ÎŤˤÆCR¤¬ÆÀ¤é¤ì¤¿È󾮺Ù˦À­ÇÙ´â¤Î²¹Ç®ÎÅË¡¤Î9¾ÉÎã ¢¡ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾
65ºÐ°Ê¾å¤ÎC·¿ËýÀ­´Î¼À´µ¤Îͽ¸å¡¦´Î´âȯ´âΨ ¢¡´Î±ê ¾
6cmÂç¤Îº¿¹ü¾åãÝ¥ê¥ó¥ÑÀឰܤȸ¶È¯Á㤬²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŤÇÀ©¸æ¤Ç¤­¤¿¿Ê¹Ô¿©Æ»´â¤Î°ìÎã ¢¡ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾
6ǯ°Ê¾å¤ÎĹ´üÀ¸Â¸¤òÆÀ¤Æ¤¤¤ëÃøÌÀ¤Ê´Îž°Ü¤òȼ¤¦½éȯ°ß´â¤Î1Îã ¢¡°ß´â ¾
7 ǯ¤Î·Ð²á´Ñ»¡¤Î¤Î¤Á¾Ã²½´É½Ð·ì¤Çȯ¾É¤·¤¿½½Æó»ØÄ²¸¶È¯ GIST ¤Î 1 Îã¡¡ ¢¡GIST ¾
76ºÐ°Ê¾å¤Î¹âÎð¼Ô¾®ºÙ˦ÇÙ´â¤ËÂФ¹¤ëCarboplatin,EtoposideÊ»ÍÑÎÅË¡ ¢¡¾®ºÙ˦´â ¾
80ºÐ°Ê¾å¹âÎð¼ÔÇÙ´â´µ¼Ô¤Î¼£ÎÅÀ®ÀÓ¡¡¡¦¡¦¡¦¹âÎð¼ÔÇÙ´â¤Ë¤ª¤±¤ë¼£ÎŤΰÌÃÖÉÕ¤±¤ò¹Ô¤¦ÌÜŪ¤Ç¡¢»Ü¹Ô¤·¤¿¼£ÎÅË¡¤Èͽ¸å¤Ë½ÅÅÀ¤ò¤ª¤¤¤ÆÎ×¾²Åª¸¡¡¦¡¦ ¢¡ÇÙ´â ¾
A Breast Cancer Patient with Myelodysplastic Syndrome Postoperatively Treated by Radiation and Tamoxifen Administration ¡ÝA Case Report33-06
A Pilot Study of Weekly Paclitaxel Administration for Patients with Relapsed Cervical Cancer after Heavy Medication ¢¡£··îÂ裴½µ¡§£²£´Æü¡ÊÆü¡Ë ¾
A Translation of the Multidimensional Affect and Pain Survey (MAPS) from English to Japanese30-05
ABCF2ÃÁÇòȯ¸½¤Ï,ÍñÁãÌÀºÙ˦Á£´â¤Î¹³´âºÞ´¶¼õÀ­¤ª¤è¤Óͽ¸å¤òͽ¬¤·¤¦¤ë¤«?¡¡¡Ý¥ª¡¼¥À¡¼¥á¥¤¥É°åÎŤòÌܻؤ·¤Æ¡Ý ¢¡9·îÂ裱½µ¡Ê1Æü¡Ë ¾
ABC¥È¥é¥ó¥¹¥Ý¡¼¥¿¡¼¤ÈÌôºÞ±þÅúÀ­¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡²½³ØÎÅË¡ ¾
adenoid cystic carcinoma¤ËÂФ·¤Æconcurrent chemoradiation therapy¤¬Ãø¸ú¤·¤¿°ìÎã ¢¡»ÒµÜ·Û´â ¾
Adjuvant¡¡Chemotherapy¤ò¤á¤°¤ëControversy31-02
ADM,CDDP,ETP,5-FUÊ»ÍÑÎÅË¡¤Ë¤Æ´°Á´´²²ò¤òÆÀ¤é¤ì¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡°ß´â ¾
AFP¤ª¤è¤ÓPIVKA-II»ºÀ¸°ß´â¤Î1Îã ¢¡£±£°·î£±Æü£Õ£Ð ¾
Aggressive B-cell Non-Hodgkin's Lymphoma¤ËÂФ¹¤ë¼«²È¤·ì´´ºÙ˦°Ü¿¢ ¢¡°­À­¥ê¥ó¥Ñ¼ð ¾
AIDS¤Ë¹çÊ»¤¹¤ë°­À­¥ê¥ó¥Ñ¼ð¡¡¡¦¡¦¡¦Ù¨Åí°­À­¥ê¥ó¥Ñ¼ð¡¦¡¦ ¢¡Æ¬ðôÉô ¾
Amrubicin¤Î³Ö½µÅêÍ¿¤Ë¤è¤ê¼ðáç¥Þ¡¼¥«¡¼¤Î²þÁ±¤¬¤ß¤é¤ì¤¿¾®ºÙ˦ÇÙ´â¤Î1Îã ¢¡ÇÙ´â ¾
AnastrozoleÎÅË¡¤¬ÁÕ¸ú¤·¤¿ÇÙ¡¦¶»Ë잰ܤòȼ¤¦¿Ê¹ÔÆý´â¤Î1Îã ¢¡Æý´â ¾
Angiotensin II blocker¤òÍѤ¤¤¿ºÆÇ³À­Á°Î©Á£´â¼£ÎŤδðÁäÈÎ×¾² ¢¡Á°Î©Á£´â ¾
Angiotensin-II(AT-II)Ê»ÍÑPharmacokinetics Modulating Chemotherapy(PMC)¾º°µÊÑˡưÃí²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿Â¿È¯´Îž°Ü¥ê¥ó¥ÑÀឰܿʹ԰ߴâ¤Î1Îã ¢¡Å¾°ÜÀ­´Î¡´â ¾
Anthracycline¤ª¤è¤ÓTaxaneÂÑÀ­ºÆÈ¯Æý´â¤ËÂФ¹¤ëCapecitabine¤Î»ÈÍѷи³ ¢¡2·î ¾
Ara-CÂçÎÌÎÅË¡¤ò´Þ¤à¶¯²½ÎÅË¡¸å,IJ´ÉÀü¹¦,¾®Ä²·ìÀò¾É¤ò¤­¤¿¤·¤¿µÞÀ­¹ü¿ñÀ­Çò·ìɤÎ1Îã ¢¡Çò·ìÉ ¾
Asian Trends in Prostate Cancer Hormone Therapy ¢¡Á°Î©Á£´â ¾
ATL¤Îʬ»ÒÉÂÍý¡¡¡¦¡¦¡¦¿·¤·¤¤¥ê¥ó¥Ñ¼ð¤ÎʬÎप¤è¤Ó¼£ÎÅ ¡¡ ATLºÙ˦¤Ë¤Ä¤¤¤Æ¡¢¸½ºßÌÀ¤é¤«¤Ë¤Ê¤Ã¤Æ¤¤¤ë¾ðÊ󡦡¦ ¢¡°­À­¥ê¥ó¥Ñ¼ð ¾
Attenuated familial adenomatous polyposis(AFAP)¤òµ¿¤Ã¤¿°Û»þÀ­Â¿È¯ÂçIJ´â¤Î1Îã ¢¡£´·îÂ裱½µ¡§£²Æü¡ÊÅÚ¡Ë Â¾
Aurora¥­¥Ê¡¼¥¼¤È¤¬¤ó¡¡¡¦¡¦¡¦Aurora¥­¥Ê¡¼¥¼¥Õ¥¡¥ß¥ê¡¼¤Îµ¡Ç½ Aurora-A Aurora-B A¡¦¡¦ ¢¡¥²¥Î¥à ¾
A·²ÍÏÏ¢¶Ý´¶À÷¤ò¹çÊ»¤·¤¿ÈØÉô¶ÚÆùÆâ³¤Ìʾõ·ì´É¼ð ¢¡£¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾
Barrett¿©Æ»´â¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡¿©Æ»´â ¾
Barrett¿©Æ»Á£´â¡¡¡¦¡¦¡¦Èæ³ÓŪ¤Þ¤ì¤Ê¼ðáç¤Î¿ÇÃǤȼ£ÎÅ­¶¡¦¡¦ ¢¡¿©Æ»´â ¾
Basedow ɤòÄ褷¤¿¶¶ËÜɤËÀ¸¤¸¤¿¹Ã¾õÁ£ MALT ¥ê¥ó¥Ñ¼ð¤Î 1 Îã¡¡ ¢¡£²·îÂ裲½µ¡§£±£±Æü¡Ê¶â¡Ë ¾
BisphosphonateÎÅË¡¤¬¹üž°Ü¤ËÍ­¸ú¤Ç¤¢¤Ã¤¿Æý´â¿¡´ïž°ÜºÆÈ¯¤Î1¾ÉÎã ¢¡¹üž°Ü ¾
BisphosphonateÎÅË¡¤Ë¤è¤Ã¤Æ¹üž°Ü¤ÎÄˤߤ¬·Ú¸º¤·¤¿3¾ÉÎã ¢¡¹üž°Ü ¾
 ¢¡3922°ß´â ¾
BNP¤¬Â¿ºÞÊ»ÍѲ½³ØÎÅË¡¤Ë¤ª¤±¤ë¿´¶ÚÆÇÀ­¤Îɾ²Á¤ËÍ­ÍѤǤ¢¤Ã¤¿2ÍÄ»ùÎã ¢¡£¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾
 ¢¡3738°­À­¥ê¥ó¥Ñ¼ð ¾
B·¿´Î¹ÅÊѤ˹çÊ»¤·¤¿Aeromonas hydrophila ÇÔ·ì¾É¤Î1˶¸¡Îã ¢¡´Î¡´â ¾
C ·¿´Î±ê¤Ë¤ª¤±¤ë½É¼çÌȱ֤βòÀϤȤ½¤Î¿ÊÊâ ¢¡´Î¡´â ¾
c-kitÍÛÀ­Ê¿³ê¶Ú¡¦¿À·Ðº®¹ç·¿¾®Ä²GIST¤Î1Îã ¢¡GIST ¾
cag PAI¤È°ßȯ´â¡¡¡¦¡¦¡¦CagA cag PAI¡¡ p53¡¡¡¦¡¦ ¢¡¥Ô¥í¥ê¶Ý ¾
Cancer Prevention¡¡¡¦¡¦¡¦Âè12²óncology forum¤Ç¤Î¸¡Æ¤ÆâÍÆ¤ò¤Þ¤È¤á¤¿¡£¡¡¤¬¤óͽËɤοÊŸ¤Èº£¸å¤ÎÀïά¤Ë¡¦¡¦ ¢¡2·îÂè4½µ ¾
Capecitabine-TrastuzumabÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿PaclitaxelÉÔ±þÀ­ºÆÈ¯Æý´â¤Î1¾ÉÎã ¢¡5·î ¾
Capecitabine¤¬Ãø¸ú¤·¤¿ºÆÈ¯Æý´â¤Î1Îã ¢¡2·î ¾
Capecitabine¤ÈDoxifluridine¤ÎÌôʪưÂÖ¤ÎÈæ³Ó¸¡Æ¤ ¢¡²½³ØÎÅË¡ ¾
Carboplatin ¡Ý¤³¤ì¤«¤é¤ÎÆý´â¼£ÎÅÌô ¢¡8·îÂ裴½µ¡¡£²£¶Æü ¾
Carboplatin+Docetaxel¤Ë¤è¤ë²½³ØÎÅË¡¤¬Ãø¸ú¤·¤¿¹âÎð¼ÔÈ󾮺Ù˦ÇÙ´â¤Î1Îã ¢¡ÇÙ´â ¾
Carboplatin+EtoposideÊ»ÍѲ½³ØÎÅË¡¤ª¤è¤ÓÊü¼ÍÀþÎÅˡƱ»þÊ»ÍѤ¬Í­¸ú¤Ç¤¢¤Ã¤¿¶»Á£´â¤Î1Îã ¢¡¶»Éô ¾
Carboplatin+Weekly Paclitaxe1Ê»ÍÑÎÅË¡¤Ë¤Æ°Àγ»¶ÉÛ·¿ÇÙž°Ü¤¬´°Á´¾Ã¼º¤·¤¿ÇÙÁ£´â¤Î1Îã ¢¡ÇÙ´â ¾
Carboplatin¤ÈDocetaxel¤Ë¤è¤ëÇÙ´â²½³ØÎÅË¡»þ¤Î·ì¾®Èĸº¾¯´ËϺîÍѤ˴ؤ¹¤ë¸¡Æ¤ ¢¡ÇÙ´â ¾
Carboplatin¤ÈPaclitaxel¤ÎËè½µÅêÍ¿¤¬Ãø¸ú¤·¤¿µ¤´É»Ù٨ʿ¾åÈé´â¤Î1Îã ¢¡Ù¨Ê¿¾åÈé´â ¾
Carmofur(HCFU)¤òÍѤ¤¤¿ÂçIJ´â¤Î½ÑÁ°²½³ØÎÅË¡ ¢¡ÂçIJ´â ¾
CD-DSTË¡¤òÍѤ¤¤¿´ÎºÙ˦´â¤ËÂФ¹¤ë¹³´âºÞ´¶¼õÀ­»î¸³ ¢¡´Î¡´â ¾
CDDP+5-FU+ADMÊ»ÍѲ½³ØÊü¼ÍÀþÎÅË¡¤Ë¤ÆCR¤¬ÆÀ¤é¤ì¤¿Ê¢Éô¥ê¥ó¥ÑÀáž°ÜÍÛÀ­¤Î¿ȯ¿Ê¹Ô¿©Æ»´â¤Î1Îã ¢¡¿©Æ»´â ¾
CDDP+5-FU¤Î´Ö·çŪ´ÎưÃí¤¬´Î¸¶È¯Á㤪¤è¤Ó¿ȯÇÙž°ÜÁã¤ËÁÕ¸ú¤·¤¿´ÎºÙ˦´â¤Î1Îã ¢¡´Î¡´â ¾
CDDP+5-FUÌë´ÖÅêÍ¿¤Ë¤è¤ëChronomodulationÎÅË¡¤ò»Ü¹Ô¤·¤¿¿Ê¹Ô°ß´â¤Î3Îã ¢¡°ß´â ¾
CDDP+CPT-11ÎÅË¡¤ª¤è¤ÓGemcitabineÎÅË¡¤Ë¤ÆÄ¹´üÀ¸Â¸¤¬²Äǽ¤È¤Ê¤Ã¤¿ÃÀǹ´âºÆÈ¯¤Î1Îã ¢¡£²·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾
CDDP,CPT-11,5-FU¤Ë¤è¤ë´Îư̮²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿´Î³°Å¾°Ü¤òÍ­¤¹¤ëÂçIJ´â´Îž°Ü¤Î1Îã ¢¡·ëIJ´â ¾
CDDP,TS-1Ê»ÍÑÊü¼ÍÀþÎÅË¡¤Ë¤è¤êÁÈ¿¥³ØÅª¤Ë¼ðáçºÙ˦¤Î¾Ã¼º¤¬Ç§¤á¤é¤ì¤¿¿Ê¹Ô¾å³Ü´â¤Î1Îã ¢¡¾å³Ü´â ¾
CDDP,VDS,MMCÊ»ÍѲ½³ØÎÅË¡¡¦¶»ÉôÊü¼ÍÀþ¼£ÎŸå¤Ë¼ê½Ñ¤¬¹Ô¤ï¤ì¤¿¶É½ê¿ÊŸ·¿È󾮺Ù˦ÇÙ´â¤Î½Ñ¸åÇÙÆÇÀ­¤Ë´Ø¤¹¤ë¸¡Æ¤ ¢¡È󾮺Ù˦´â ¾
CDDP,VinorelbineÊ»ÍÑÎÅË¡¤¬Ãø¸ú¤·¤¿´Îž°Ü¤òȼ¤¦ÇÙÂçºÙ˦´â¤Î1Îã ¢¡ÂçºÙ˦´â ¾
CDDP¤Ë¤è¤ëÇÙ´â²½³ØÎÅË¡¤Ë¤ª¤±¤ëOndansetron Hydrochloride¤È¥¹¥Æ¥í¥¤¥ÉºÞ¤ÎÊ»ÍѤ˴ؤ¹¤ë¸¡Æ¤ ¢¡ÇÙ´â ¾
CDDPÊ¢¹ÐÆâÅêÍ¿¡ÜTS-1Ê»ÍÑÎÅË¡¤Ë¤è¤ê´âÀ­Ê¢¿å¤¬¾Ã¼º¤·¤¿¿Ê¹ÔÀ­°ß´â¤Î1Îã39-02
Cdx2¤È°ß´â ž¼Ì°ø»Ò¤È¾Ã²½´É´â¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡£¸·î£±Æü ¾
CEA¤Î¿ä°Ü¤«¤é¤ß¤¿ÂçIJ´â´Îž°Ü(H3)¤ËÂФ¹¤ëDegradable Starch Microsphere(DSM),Adriamycin(ADM),Mitomycin C(MMC)´ÎưÃíÎÅË¡¤Î¸ú²ÌȽÄê ¢¡Å¾°ÜÀ­´Î¡´â ¾
CEF Followed Docetaxel¤Ë¤è¤ëÆý´â½ÑÁ°²½³ØÎÅË¡¤Î°ÂÁ´À­,Í­¸úÀ­¤Ë´Ø¤¹¤ë¸¡Æ¤ ¢¡²½³ØÎÅË¡ ¾
Changes in Hepatic Parenchymal Ultrasound Images in Tamoxifen Medication Patients ¢¡Êü¼ÍÀþ´ØÏ¢ ¾
Cimetidine¤Ë¤è¤ëSialyl Lewis(sLe)¹³¸¶¹âȯ¸½´â¤Î·ì´ÉÆâÈ館¤ÎÀÜÃåÍÞÀ© ¢¡²½³ØÎÅË¡ ¾
Cis-Platinum½ùÊüÀ­Injectable Drug Carrier ¢¡²½³ØÎÅË¡ ¾
Cisplatin and Gemcitabine in Patients with Metastatic Cervical Cancer31-07
Cisplatin(CDDP)+Paclitaxel(PTX)Ê¢¹ÐÆâÅêÍ¿¤Ë¤è¤êÊ¢¿å¤¬·Ú²÷¤·¤¿°­À­Ê¢ËìÃæÈé¼ð¤Î1Îã ¢¡°­À­ÃæÈé¼ð ¾
Cisplatin+DocetaxelÊ»ÍѲ½³ØÎÅË¡¤Ë¤è¤ê´°Á´´²²ò¤¬ÆÀ¤é¤ì¤¿¶É½ê¿Ê¹Ô´üÇÙ٨ʿ¾åÈé´â¤Î1Îã ¢¡Ù¨Ê¿¾åÈé´â ¾
Cisplatin+GemcitabineÊ»ÍѲ½³ØÎÅË¡¤¬Ãø¸ú¤·¤¿¸ý¹Ð´âºÆÈ¯Á´¿Èž°Ü¤Î1¾ÉÎã ¢¡¸ý¹Ð´â ¾
Cisplatinum,5-Fluorouracil,Levofolinate Calcium´Îư̮ÃíÆþ,ÂçÆ°Ì®ÃíÆþÊ»ÍÑÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿°ß´â¿ȯ´Îž°Ü¤Î1Îã ¢¡°ß´â ¾
Cisplatin¤Î¿´Ç¹ÆâÃíÆþ¤¬ÁÕ¸ú¤·¤¿Æý´â¿´Ç¹Å¾°Ü¤Î1Îã ¢¡2·î ¾
Cisplatin´ÎưÃíÎÅË¡¤ÈTS-1·Ð¸ýÅêÍ¿¤¬ÁÕ¸ú¤·¤¿ç¹Á£Ë¼ºÙ˦´â´Îž°Ü¤Î1Îã ¢¡Å¾°ÜÀ­´Î¡´â ¾
CisplatinͶȯ°­¿´¡¦ÓÒÅǤËÂФ¹¤ëRamosetron¤ÈDexamethasoneÊ»ÍÑÎÅË¡¤ÎÎ×¾²¸ú²Ì-Dexamethasone¤ÎÍÑÎ̳Îǧ»î¸³- ¢¡¸ý¹Ð´â ¾
Cladribine¡¡¡¦¡¦¡¦Âè­µÁê»î¸³¡¡³¤³°¤Ç¤ÎÂè­¶Áê»î¸³¡¦¡¦ ¢¡²½³ØÎÅË¡ ¾
Cladribine¤ÎÅêÍ¿¤Ë¤è¤ê´²²òƳÆþ¤ª¤è¤Ó¹ü¿ñÀþ°Ý²½¤ÈÈ鿾¤Î²þÁ±¤¬ÆÀ¤é¤ì¤¿Hairy Cell Leukemia ¢¡¤½¤Î¾¤Î´â ¾
Clinical Benefit¤«¤é¤ß¤¿¿Ê¹Ôç¹´â¤ËÂФ¹¤ëGemcitabine¤ÎÍ­ÍÑÀ­ ¢¡ç¹Â¡´â ¾
CMF¤Ë¤è¤ëThird-Line Chemotherapy¤¬Ãø¸ú¤·¤¿Æý¤¬¤ó½Ñ¸åÇÙž°Ü¤Î1Îã ¢¡¶»Éô ¾
Combination of Vinorelbine+Doxorubicin in Advanced Breast Cancer ¢¡Æý´â ¾
Cost-effectiveness of Letrozole versus Tamoxifen as First-line Hormonal Therapy in Treating Postmenopausal Women with Advanced Breast Cancer in Japan ¢¡£··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾
Covered Type¿©Æ»Stent¤Ë¤è¤êÎɹ¥¤ÊQOL¤¬ÆÀ¤é¤ì¤¿¿©Æ»µ¤´Éáñ¤òÍ­¤¹¤ë¶»Éô¾åÉô¿©Æ»´â¤Î1Îã ¢¡¿©Æ»´â ¾
COX-2 Á˳²Ìô¤Î¿ÌÌÀ­¤Èº£¸å¤Îư¸þ¡¡¡¦¡¦¡¦COX-1 COX-2 Èæ³Ó¡¡ ¹üÂå¼Õ¡¡ ¥¢¥Ý¥È¡¼¥·¥¹¡¡Èó¥¹¥Æ¥í¥¤¥É¹³±ê¾ÉÌô NSA¡¦¡¦ ¢¡31-1 ¾
COX-2¤È´â¼£ÎŸ¦µæ¡¡¡¦¡¦¡¦COX¤ÎºîÍÑ¡¡ ´â¤Ë¤ª¤±¤ëCOX-2¤Îȯ¸½¡¡ COX-2Á˳²ºÞ¤Ë¤è¤ë´â¼£ÎÅ¡¡ ¡¡È¯¡¦¡¦ ¢¡²½³ØÎÅË¡ ¾
CPT-11+CDDPÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿°ß´âÊ¢ËìÇÅ¼ïºÆÈ¯¤Î1Îã ¢¡£··îÂ裵½µ¡§£³£±Æü¡ÊÆü¡Ë ¾
CPT-11+TS-1Ê»ÍѲ½³ØÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿´Î¡¦ÇÙ¡¦¥ê¥ó¥ÑÀឰܺÆÈ¯·ëIJ´â¤Î1Îã33-06
CPT-11+TS-1Ê»ÍѲ½³ØÎÅË¡¤Ë¤è¤êÊ¢ËìÇż郎¾Ã¼º¤·CR¤È¤Ê¤Ã¤¿1Îã ¢¡·ëIJ´â ¾
CPT-11+UFT-EÊ»ÍÑÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿1¾ÉÎã ¢¡·ëIJ´â ¾
CPT-11/5-FU/l-LeucovorinÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿¿Ê¹ÔÂçIJ´â4¾ÉÎã ¢¡ÂçIJ´â ¾
CPT-11/CDDPÊ»ÍѲ½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿´Îž°Ü¤òȼ¤¦AFP»ºÀ¸°ß´â¤Î1Îã ¢¡°ß´â ¾
CPT-11¤¬Í­¸ú¤Ç¤¢¤Ã¤¿¿©Æ»¾®ºÙ˦´â¤Î1Îã ¢¡¿©Æ»´â ¾
CPT-11¤ò´Þ¤à¿ºÞÊ»ÍѲ½³ØÎÅË¡ :¿Ê¹Ô°ß´â¤ËÂФ¹¤ë¿ºÞÊ»ÍѲ½³ØÎÅË¡ ¢¡°ß´â ¾
CPT-11¥Ù¡¼¥¹¤Î²½³ØÎÅË¡¤Ë¤è¤ê3ǯ¤Ë¤ï¤¿¤êĹ´üÀ¸Â¸¤¬ÆÀ¤é¤ì¤¿ÂçIJ´â¤Î1Îã ¢¡ÂçIJ´â ¾
CPT-11´ÎưÃí+UFTÆâÉþ¤¬Í­¸ú¤Ç¤¢¤Ã¤¿Ä¾Ä²´â´Îž°Ü¤Î2Îã ¢¡·ëIJ´â ¾
CPT-11Äñ¹³À­ÀÚ½üÉÔǽ¿Ê¹ÔÂçIJ´â¤ËÂФ·Oxaliplatin(L-OHP)/5-FU/l-LV¤òÍѤ¤¤¿Chronotherapy¤¬Í­¸ú¤Ç¤¢¤Ã¤¿1Îã ¢¡ÂçIJ´â ¾
CPT-11Ê»ÍÑLow-Dose CDDP+5-FUÎÅË¡¤¬ÁÕ¸ú¤·¤¿´Îž°Ü,ÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀឰܤòȼ¤¦¿Ê¹Ô°ß´â¤Î1Îã ¢¡Å¾°ÜÀ­´Î¡´â ¾
CrohnɤÈIJ´â¡¡¡Ý±ê¾ÉÀ­Ä²¼À´µ¤Èȯ´â¡¡¡¦¡¦¡¦CrohnÉ¡¡ÂçIJ´âȯÀ¸¤Îµ¡½ø¡¡ £É£Â£Ä¤Ë¹çÊ»¤¹¤ëÂçIJ´â¡Ê£Ã£Á£Ã¡Ë¤ÎÉÑÅÙ¡¦Î×¾²Áü¡¡ ¡¦¡¦ ¢¡£±£°·î£±Æü£Õ£Ð ¾
CT¡¤ERCP¡¡¡¦¡¦¡¦ç¹´â¿ÇÎŤθ½¾õ¤ÈÁá´üȯ¸«¤Î¹©Éס¿¥Ð¥ë¡¼¥ó¥«¥Æ¡¼¥Æ¥ë繴ɤ±Æ¡¾°µÇ÷»£±ÆË¡¡¿ERP ¤Î¼êµ»¤ò¡¦¡¦76
CT¤Ë¤è¤ë°ß´âÊ¢Ëìž°Ü¿ÇÃǤÎÍ­ÍÑÀ­¡¡¡¦¡¦¡¦½ÑÁ°Ê¢ÉôCT¸¡ºº¤ÎÎ×¾²Åª°ÕµÁ¡¦¡¦ ¢¡°ß´â ¾
CT¤Ë¤è¤ëç¹´â¤Î½ÑÁ°¥¹¥Æ¡¼¥¸¥ó¥°¡Ý¸åÊ¢Ëì¿»½á¤Ê¤é¤Ó¤Ë¥ê¥ó¥ÑÀáž°Ü¿ÇÃÇ¡¼ ¢¡ç¹Â¡´â ¾
CTÆ©»ë¤òÍѤ¤¤¿ÇÙ°­À­¼ðáç¤ËÂФ¹¤ë·ÐÈéŪÅà·ë¼£ÎŤμºݠ¢¡29-3 ¾
Cyclophosphamide,Vincristine,Dacarbazine¤Î3ºÞÊ»ÍÑÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿°­À­³ì¿§ºÙ˦¼ð¤Î1Îã ¢¡ÈéÉæ ¾
C·¿´Î±ê¤ËȯÀ¸¤·¤¿À®¿Í´Î²ê¼ð¤Î1ÀÚ½üÎã¡¡¡¦¡¦¡¦¡¦¡¦39-01
C·¿´Î±ê¥¦¥¤¥ë¥¹¤Î±¡Æâ´¶À÷¡¡¡¦¡¦¡¦°åÎŽ¾»ö¼Ô¤«¤é´µ¼Ô¤Ø¤Î´¶À÷¡¡ ´µ¼Ô¤«¤é°åÎŽ¾»ö¼Ô¤Ø¤Î´¶À÷¡¡ ´µ¼Ô¤«¤é´µ¼Ô¤Ø¤Î´¶À÷¡¡¡¦¡¦ ¢¡´Î±ê ¾
C·¿´Î±ê¥ï¥¯¥Á¥ó³«È¯¸¦µæ¤Î¸½¾õ¡¡¡¦¡¦¡¦HCV°äÅÁ»Ò¹½Â¤¤È¥¦¥£¥ë¥¹ÃÁÇò¼Á¡¡ HCV¤Î¥ï¥¯¥Á¥ó³«È¯¤Ë¤ª¤±¤ëÌäÂêÅÀ¡¡ HCV¤Î¥ï¡¦¡¦ ¢¡´Î±ê ¾
C·¿´Î±ê¥ï¥¯¥Á¥ó³«È¯¸¦µæ¤Î¸½¾õ¡¡¡¦¡¦¡¦HCV°äÅÁ»Ò¹½Â¤¤È¥¦¥£¥ë¥¹ÃÁÇò¼Á¡¡ HCV¤Î¥ï¥¯¥Á¥ó³«È¯¤Ë¤ª¤±¤ëÌäÂêÅÀ¡¡ HCV¤Î¥ï¡¦¡¦ ¢¡´Î±ê ¾
C·¿´Î±ê¥ï¥¯¥Á¥ó³«È¯¸¦µæ¤Î¸½¾õ¡¡¡¦¡¦¡¦HCV°äÅÁ»Ò¹½Â¤¤È¥¦¥£¥ë¥¹ÃÁÇò¼Á¡¡ HCV¤Î¥ï¥¯¥Á¥ó³«È¯¤Ë¤ª¤±¤ëÌäÂêÅÀ¡¡ HCV¤Î¥ï¡¦¡¦ ¢¡59-07 ¾
C·¿´Î±ê¥ï¥¯¥Á¥ó³«È¯¸¦µæ¤Î¸½¾õ¡¡¡¦¡¦¡¦HCV°äÅÁ»Ò¹½Â¤¤È¥¦¥£¥ë¥¹ÃÁÇò¼Á¡¡ HCV¤Î¥ï¥¯¥Á¥ó³«È¯¤Ë¤ª¤±¤ëÌäÂêÅÀ¡¡ HCV¤Î¥ï¡¦¡¦ ¢¡59-07 ¾
C·¿´Î±ê´µ¼Ô¤ËȯÀ¸¤·¤¿´Î°­À­¥ê¥ó¥Ñ¼ð¤Î1Î㤪¤è¤ÓËÜË®Êó¹ðÎã¤Îʸ¸¥Åª¹Í»¡ ¢¡°­À­¥ê¥ó¥Ñ¼ð ¾
C·¿ËýÀ­´Î±ê¤Ë¤ª¤±¤ë¾åÊ¢Éô²Ã²¹¸ú²Ì¤Î¸¡Æ¤(Âè1Êó)22²ó¡¡Âç²ñ
C·¿ËýÀ­´Î±ê¤Ë¤Æ·Ð²á´Ñ»¡Ãæ¤Ë²«áÕ¤ò·Àµ¡¤Ëȯ¸«¤µ¤ì¤¿Ê¢Éô¸¶È¯Èó¥Û¥¸¥­¥ó¥ê¥ó¥Ñ¼ð¤Î1Îã ¢¡°­À­¥ê¥ó¥Ñ¼ð ¾
C·¿ËýÀ­´Î±ê¤Ë¹çÊ»¤·¤¿´ÎÆâÃÀ´ÉÁ£¼ð¤Î1Î㡽²èÁü½ê¸«¤òÃæ¿´¤Ë¡½ ¢¡´ÎÆâÃÀ´É´â ¾
C·¿ËýÀ­´Î±ê¤ËÂФ¹¤ë´Îȯ´âÍÞÀ©¤òÌÜŪ¤È¤·¤¿IFN¼£ÎÅ ¢¡´Î±ê ¾
C·¿ËýÀ­´Î±ê¤Î²¹Ç®ÎÅË¡¤Ë¤è¤ë´ÎÁÈ¿¥Æâ°äÅÁ»Òȯ¸½¤ÎÊѲ½ ¢¡21-Supplement ­¶ ¾
¡¡

¥Ú¡¼¥¸¤ÎÀèÆ¬¤ËÌá¤ë¡¡¡¡ 1¡¿10¡¡ 2¡¿10¤Ø¡¡ 3¡¿10¤Ø¡¡ 4¡¿10¤Ø¡¡ 5¡¿10¤Ø¡¡ 6¡¿10¤Ø¡¡ 7¡¿10¤Ø¡¡ 8¡¿10¤Ø¡¡ 9¡¿10¤Ø¡¡ 10¡¿10¤Ø¡¡

¡¡Ãøºî¸¢Ë¡¤Î´Ø·¸¾å¡¢Í½¹ð¤Ê¤¯Ê£¼Ì¥µ¡¼¥Ó¥¹¤òÄä»ß¤·¤¿¤êÃøºî¸¢ÎÁ¤ò²þÄꤹ¤ë¾ì¹ç¤¬Í­¤ê¤Þ¤¹¡£